Stockscreener 앱 받기
0.16
86.55%
-1.03
전일 마감가:
$1.19
열려 있는:
$0.6
하루 거래량:
100
Relative Volume:
1.32
시가총액:
$N/A
수익:
$1.04M
순이익/손실:
$-49.01M
주가수익비율:
-0.0144
EPS:
-11.109
순현금흐름:
$-17.34M
1주 성능:
-86.55%
1개월 성능:
-86.55%
6개월 성능:
-86.55%
1년 성능:
-86.10%
1일 변동 폭
$0.60
$0.60
1주일 범위
$0.60
$0.60
52주 변동 폭
$0.60
$1.19
Orgenesis Inc Stock (ORGS) Company Profile
Compare ORGS vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
0.60 | 0 | 1.04M | -49.01M | -17.34M | -11.11 |
VRTX
Vertex Pharmaceuticals Inc
|
449.37 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.44 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
750.63 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.90 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.60 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-12-20 | 개시 | Dawson James | Buy |
Orgenesis Inc 주식(ORGS)의 최신 뉴스
ORGS (Orgenesis) PB Ratio : (As of Mar. 31, 2026) - GuruFocus
Stock List: Research Stocks from Around the World - gurufocus.com
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
Orgenesis Inc. 2024 Annual 10-K Report: Financials, Equity, and Major Agreements Overview - Minichart
ORGS: Severe liquidity issues and a $49M net loss raise substantial doubt about ongoing operations - TradingView
Orgen 2023 Form 10-K: $1.035M Revenue, $(49.01)M Net Loss - TradingView
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio (2026-03-26) - Seeking Alpha
Okogen Expands Antiviral Pipeline with Ranpirnase Acquisition, Targeting Multiple Therapeutic Areas - citybuzz -
Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc.. - marketscreener.com
Orgenesis Inc stock advances on cellular therapy breakthroughs amid biotech funding surge - AD HOC NEWS
Orgenesis Inc stock advances on new cell therapy partnership amid biotech rally - AD HOC NEWS
Orgenesis Expands Board and Appoints New Chief Financial Officer - The Globe and Mail
Orgenesis appoints new directors and chief financial officer - Investing.com South Africa
Orgenesis appoints new directors and chief financial officer By Investing.com - Investing.com Australia
Orgenesis adds Adam Pelavin and Yaron Adler to board; Doug Karriker named CFO - TradingView
Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026 - marketscreener.com
Patience Required for Orgenesis Investors as Strategic Model Takes Shape - AD HOC NEWS
The Truth About Orgenesis Inc (ORGS): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Orgenesis (NASDAQ:ORGS) Trading Up 300% – Here’s What Happened - Defense World
GLP-1 Receptor Agonist Market to Witness Massive Growth by 2033 | Perrigo Company PLC, 3M Company, Bausch Health - Weekly Voice
Orgenesis Issues Alpha Warrant in New Financing Deal - TipRanks
Orgenesis issues warrant for 3.29 million shares tied to $1 million loan - Investing.com
Orgenesis Signs Warrant Issuance Agreement With Alpha Prosperity Fund - TradingView
The Truth About Orgenesis (ORGS): Tiny Biotech, Massive Hype – But Should You Touch It? - AD HOC NEWS
Is Orgenesis Inc. (45O) stock a safe buy pre earnings2025 Earnings Surprises & Stock Timing and Entry Methods - Улправда
Retail Trends: Is Orgenesis Inc 45O stock a safe buy pre earnings2025 Market WrapUp & AI Powered Buy/Sell Recommendations - moha.gov.vn
Aug Gainers: Is Orgenesis Inc 45O stock a safe buy pre earningsInflation Watch & Verified Swing Trading Watchlists - moha.gov.vn
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant
Published on: 2025-12-23 22:10:30 - earlytimes.in
Regenerative Therapies Market Forecast Through 2032 - openPR.com
Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast - Defense World
Victor Miller Joins NorthStar Medical Radioisotopes, LLC as Chief Financial Officer - Business Wire
Is Oriental Culture Holding LTD a good long term investmentUtilities Sector Analysis & Crush the Market with Breakout Winners - earlytimes.in
Financial Contrast: Pharmaxis (OTCMKTS:PXSLY) and Orgenesis (NASDAQ:ORGS) - Defense World
What analysts say about GoPro Inc stockResistance Zone Identification & Machine Learning Stock Picks, Daily - earlytimes.in
How Orgenesis Inc. (45O) stock trades in high volatility2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Is Orgenesis Inc. (45O) stock suitable for passive index fundsWeekly Gains Report & Precise Swing Trade Alerts - Newser
Apex Tech Acquisition Inc files for IPO of up to $60 million - marketscreener.com
Is Orgenesis Inc. (45O) stock protected from inflation2025 Retail Activity & Fast Exit Strategy with Risk Control - Newser
Will Orgenesis Inc. (45O) stock split increase liquidityJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
How Orgenesis Inc. (45O) stock compares with top peersShort Setup & Accurate Entry/Exit Alerts - Newser
Why Orgenesis Inc. (45O) stock attracts HNW investorsJuly 2025 Final Week & Proven Capital Preservation Tips - Newser
Onconase (Ranpirnase) | Benefits and Side Effects - Mesothelioma.net
Will Orgenesis Inc. (45O) stock beat international competition2025 Market Trends & AI Forecasted Entry and Exit Points - Newser
Orgenesis (NASDAQ:ORGS) Stock Price Up 257.1% – Here’s Why - Defense World
Will Orgenesis Inc. (45O) stock gain from lower interest ratesProduct Launch & Verified Momentum Stock Alerts - newser.com
Orgenesis Inc (ORGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
자본화:
|
볼륨(24시간):